Picture EBD Group ChinaBio Partnering Forum 2020 Digital Event CBPF2020 650x80
Person › Details

Mary-Jane Elliott (Consilium Strategic Communications Ltd. (CSC))

Elliott, Mary-Jane (Consilium SC 201307– Managing Partner + Co-founder before M:Communications)


Organisations Organisation Consilium Strategic Communications Ltd. (CSC)
  Former/major organisation M:Communications (division of King Worldwide)
  Group King Worldwide (Group)
Products Product public relations / investor relations / marcom (services)

Bone Therapeutics S.A.. (9/17/13). "Press Release: Bone Therapeutics Appoints Wim Goemaere as Chief Financial Officer". Gosselies.

BONE THERAPEUTICS, the leading biopharmaceutical company focused on innovative cell therapy products for the treatment of bone diseases, announces today that Wim Goemaere has joined the Company as Chief Financial Officer (CFO).

Wim is a highly experienced senior financial executive with over 25 years international business experience, the majority of which he spent within the biotechnology space. Wim joins Bone Therapeutics from Devgen, a Belgium-based multinational agrobiotech company listed on the NYSE Euronext Brussels, where he held the position of CFO for five years. He was instrumental in ensuring endorsement of Devgen in the financial markets and in the recent takeover of Devgen by Syngenta for €403 million. Furthermore, he played a vital role into the company's business expansion in Asia.

Prior to Devgen, Wim was CFO of the internationally renowned Flanders Institute for Biotechnology (VIB), which he joined in 1995, and played a key role in the Institute's development from startup to one of the world's leading research bodies in life sciences.

Wim began his career at BP where he held various finance roles with increasing responsibility until leaving the Company to pursue his career in biotech. Wim holds a degree in Applied Economics from KU Leuven (Belgium).

Enrico Bastianelli, Chief Executive Officer of Bone Therapeutics, commented: "We are delighted that Wim is joining Bone Therapeutics. His extensive experience of both the financial and biopharmaceutical sectors will be invaluable to the Company as we progress to the next stage of our development."

Wim Goemaere, Chief Financial Officer of Bone Therapeutics, commented: "I am pleased to be joining Bone Therapeutics at such a crucial time in the Company's development. With a Phase III trial ongoing for the Company's lead product PREOB® and a strong pipeline of exciting clinical stage bone disease cell therapy products, Bone Therapeutics is at a transformational point in its development. I look forward to working closely
with Enrico and the management team to ensure the Company's continuing success."

About Bone Therapeutics

Bone Therapeutics is a leading international biopharmaceutical company focused on innovative cell therapy products for the treatment of bone diseases. Utilizing the Company's unique knowledge of the bone/joint physiology and longstanding expertise in cell therapy and cell transplantation, Bone Therapeutics has created a fully integrated business with an advanced product pipeline comprising novel bone cell products, tailored inhouse production methods, and minimally invasive treatment techniques.

Bone Therapeutics' lead product, PREOB®, is an autologous bone cell product, currently in Phase III clinical trials for the treatment of osteonecrosis and nonunion fractures. Bone Therapeutics is also developing an allogeneic bone cell therapy product, ALLOB®, which is expected to enter the clinic in 2013, and MXB, a combined cellmatrix product for the treatment of large bone defects, currently in preclinical development. All of Bone Therapeutics' cell therapy products are manufactured to the highest GMP standards and protected by a rich IP estate.

The bone disease and reconstruction market is one of the largest healthcare markets in the world, with more than 4 million procedures requiring bone grafts performed annually in Europe and the USA alone.

Bone Therapeutics is operating in areas where demand for new products is high and competition is low. Founded in 2006, Bone Therapeutics is privately held and headquartered in Gosselies (south of Brussels), Belgium. Further information is available at:

For further information, please contact:

Bone Therapeutics SA
Tel: +32 (0)2 529 59 90
Enrico Bastianelli, Chief Executive Officer

Consilium Strategic Communications
Amber Bielecka, MaryJane Elliott, Lindsey Neville
Tel: +44 (0) 20 7920 2333

Record changed: 2020-04-09


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Mary-Jane Elliott

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group ChinaBio Partnering Forum 2020 Digital Event CBPF2020 650x80

» top